Sign In
Buy CRDF
$1.40
-0.110 (-7.28%)
At Close: Jun 03, 2026
Cardiff Oncology to Present at Upcoming Investor Conferences
04:05pm, Monday, 24'th Feb 2025
SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cance
Cardiff Oncology to Report Fourth Quarter 2024 Results and Provide Business Update
04:05pm, Thursday, 20'th Feb 2025
- Management will hold a conference call on Thursday, February 27 at 4:30 p.m. ET/1:30 p.m. PT - - Management will hold a conference call on Thursday, February 27 at 4:30 p.m. ET/1:30 p.m. PT -
Cardiff Oncology: Pioneering RAS-Mutated Cancer Therapies With Onvansertib
09:19am, Tuesday, 18'th Feb 2025
Cardiff Oncology's Onvansertib shows promise in treating RAS-mutated cancers, especially mCRC, with a strong therapeutic profile and potential for high returns if approved. Onvansertib's Phase II resu
Undercovered Dozen: Ubiquiti, Ready Capital, Cardiff Oncology, Vodafone +
09:00am, Saturday, 14'th Dec 2024
The 'Undercovered' Dozen series highlights lesser-covered stocks, offering fresh investment ideas and sparking community discussions on their potential. Ubiquiti Inc. shows promise with operational im
Cardiff Oncology: The Long-Awaited First-Line MCRC Data Are Here, But The Work Is Just Beginning
05:38am, Thursday, 12'th Dec 2024
Cardiff Oncology's phase 2 trial of onvansertib in mCRC shows promising preliminary data, with improved response rates in a dose-dependent manner. Onvansertib appears well tolerated and effective when
CRDF Stock Soars on Robust Efficacy Data From Colorectal Cancer Study
11:06am, Wednesday, 11'th Dec 2024
Cardiff Oncology stock rallies as initial data from a phase II study of onvansertib shows superior efficacy over SOC chemotherapy in colorectal cancer patients.
Cardiff Oncology: Beats Standard Of Care In First Line Metastatic Colorectal Cancer
05:05pm, Tuesday, 10'th Dec 2024
Cardiff Oncology's Phase 2 trial data for Onvansertib in metastatic colorectal cancer shows dose-related outperformance of standard care, with a combined ORR of 57% versus 33% in the control arm. The
Cardiff Oncology Prices Oversubscribed $40 Million Underwritten Registered Direct Offering
07:20am, Tuesday, 10'th Dec 2024
SAN DIEGO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF) (“Cardiff Oncology” or the “Company”), a clinical-stage biotechnology company leveraging PLK1 inhibition to d
Cardiff Oncology Announces Positive Initial Data from First-line RAS-mutated mCRC Clinical Trial
06:00am, Tuesday, 10'th Dec 2024
- Initial results from randomized Phase 2 CRDF-004 trial evaluating onvansertib + standard of care in RAS-mut mCRC demonstrated 64% ORR in the 30mg onvansertib dose arm versus 33% ORR in the control a
Cardiff Oncology (CRDF) Reports Q3 Loss, Tops Revenue Estimates
07:10pm, Thursday, 07'th Nov 2024
Cardiff Oncology (CRDF) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.22 per share a year ago.
Cardiff Oncology Announces Journal of Clinical Oncology Publication of Data from Phase 2 Trial in Second-line KRAS Mutant mCRC
04:30pm, Wednesday, 30'th Oct 2024
- Findings underscore that the combination of onvansertib with FOLFIRI and bevacizumab demonstrates clinical activity and is well tolerated in second-line KRAS-mutant mCRC -
Cardiff Oncology: Paramount Data Imminent In Huge First-Line mCRC Market
01:10pm, Friday, 04'th Oct 2024
Cardiff Oncology's Onvansertib shows promise in treating RAS-mutated metastatic colorectal cancer, potentially opening a massive market with an estimated $567 million to $3.78 billion in annual US sal
Cardiff: Second Half Of 2024 mCRC Data Is Major Inflection Point
02:57pm, Monday, 12'th Aug 2024
Cardiff Oncology, Inc. results from the phase 2 CRDF-004 study, using onvansertib + Folfiri + bevacizumab for the treatment of patients with RAS-mutant mCRC, expected in the 2nd half of 2024. The glob
Cardiff Oncology, Inc. (CRDF) Q2 2024 Earnings Call Transcript
11:18am, Saturday, 10'th Aug 2024
Cardiff Oncology, Inc. (NASDAQ:CRDF ) Q2 2024 Results Conference Call August 8, 2024 4:30 PM ET Company Participants Kiki Patel - Investor Relations, Gilmartin Group Mark Erlander - Chief Executive Of
Cardiff Oncology (CRDF) Reports Q2 Loss, Tops Revenue Estimates
07:01pm, Thursday, 08'th Aug 2024
Cardiff Oncology (CRDF) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.25 per share a year ago.
